**Question:** A 40 year old male patient is hospitalised with huge splenomegaly, marked sternal tenderness, and a total leucocyte count of 85,000 per cubic millimetre with large percentage of myelocytes and metamyelocytes. Which of the following drugs is best indicated for his disease?

A. Hydroxyurea
B. Cytosine arabinoside
C. Thalidomide
D. Allopurinol

**Core Concept:**

The clinical presentation described here is indicative of a hematological disorder, most likely a myeloproliferative disorder or a myelodysplastic syndrome. These conditions are characterized by the abnormal proliferation and differentiation of hematopoietic cells, leading to hypercellularity and peripheral blood cytopenias. The raised total leukocyte count with a high percentage of myelocytes and metamyelocytes suggests a condition with ineffective hematopoiesis, such as essential thrombocythemia, polycythemia vera, or chronic myeloid leukemia (CML).

**Why the Correct Answer is "A":**

Hydroxyurea (A) is the most appropriate choice among the given options. It is a nucleoside analogue that acts as a cytotoxic agent, specifically targeting rapidly dividing malignant hematopoietic cells. By inhibiting DNA synthesis and cell division, hydroxyurea helps to reduce the excessive production of immature granulocytes and lymphocytes, thereby improving the peripheral blood counts and reducing splenomegaly in these conditions.

**Why Option B and C are incorrect:**

Option B, cytosine arabinoside, is a nucleoside analogue used primarily in acute leukemia treatment. Although it can be effective in certain cases of myelodysplastic syndromes, it is not as commonly used as hydroxyurea for the management of myeloproliferative disorders with splenomegaly.

Option C, thalidomide, is primarily used in the treatment of multiple myeloma and other plasma cell disorders. It is not a first-line choice for the management of myeloproliferative disorders.

**Why Option D is incorrect:**

Option D (allopurinol) is a xanthine oxidase inhibitor primarily indicated for the management of hyperuricemia and gout. It is not appropriate for the treatment of myeloproliferative disorders or myelodysplastic syndromes associated with splenomegaly.

**Clinical Pearl:**

In conclusion, hydroxyurea is the preferred treatment option for myeloproliferative disorders with splenomegaly due to its efficacy in reducing the excessive production of granulocytes and lymphocytes. It is essential to consider the specific disease entity, as the choice of treatment may vary based on the underlying condition (e.g., polycythemia vera vs. essential thrombocythemia vs. myelodysplastic syndromes) and the stage of the disease progression.